遠東發展(00035.HK)澳洲法律訴訟案達成和解
遠東發展(00035.HK)公布有關澳洲法律訴訟,其間接全資附屬公司FEC Care Park與其他Care Park各方及Belteky各方訂立和解契據,據此,其項下之訂約方已協定按和解契據載列之條款解決法律訴訟。根據和解契據,訂約方同意訂約方必須促使其各自之律師簽署建議同意令之記錄,並向法庭尋求命令促使撤銷法律訴訟項下之申索,及Warmlink將分別向FEC Care Park及Chartbridge轉讓所持有的14% CPG股份。
集團指,基於公司對法律訴訟潛在結果以及繼續進行法律訴訟所需時間、成本及精力之評估,董事會認為,和解將減少進行法律訴訟所需之時間、成本及精力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.